HOPA News Articles
Clear filter
The Impacts of Strong Professional Relationships Between Clinical Pharmacists and Medical Science Liaisons
In this piece from the HOPA News archives, authors Megan Langer and Jake Hanlin reflect on how medical science liaisons have impacted their patient care and professional careers - and what tips they have for productively working with them.
Late-Breaking HOPA News: Belantamab Mafodotin-bmlf Returns: FDA Restores BCMA-Targeted ADC Option for RRMM
Marshall Winget, PharmD, and Bradley Yelvington, PharmD, BCOP, discuss the recent reapproval of belantamab mafodotin in BCMA-directed therapy for relapsed or refractory multiple myeloma.
Late-Breaking HOPA News: The Evolving Landscape of NPM1-Mutated AML
Moh'd Mohanad A. Al-Dabet, PhD, AHI(AMT); Katia Al-Sawalha, BSc; and Olivia White, PharmD, BCOP, review revumenib and ziftomenib for NPM-1m disease and highlight key considerations when implementing these two therapies.
A Journey of a Thousand Miles Begins with a Single Step Navigating the Path to a Leadership Position
In this personal reflection from the latest issue of HOPA News, Mary Walters, PharmD, BCOP, and Peter Stuessy, PharmD, BCOP, compare and contrast their journeys into leadership roles - and what advice they would give others on their own leadership paths.
Late-Breaking HOPA News: Lurbinectedin and Atezolizumab for Extensive-Stage Small Cell Lung Cancer
Ming-Hei Tai, PharmD, BCOP, and Alexis Chapman, PharmD, BCOP, discuss the IMforte trial concerning lurbinectedin and atezolizumab in the treatment of extensive-stage small cell lung cancer.
Late-Breaking HOPA News: The Emerging Use of Bispecific Antibodies with Chemotherapy in Diffuse Large B-Cell Lymphoma
Katelynn Granger, PharmD, BCOP, and Matthew Warrick, PharmD, BCPS, BCOP, dive into the emerging use of bispecific antibodies with chemotherapy in diffuse large B-cell lymphoma.
Late-Breaking HOPA News: Fam-trastuzumab deruxtecan-nxki for HER2 Ultralow Metastatic Breast Cancer
The ability of fam-trastuzumab deruxtecan-nxki to treat breast cancer patients with HER2 IHC 0 with positive membrane staining up to IHC 3+ has changed the treatment paradigm for metastatic disease.
